What is Generate Biomedicines, Inc.'s (GENB) StockRank?

MoatMap's StockRank for Generate Biomedicines, Inc. (GENB) is 8/100, with a Strong Sell signal. This is a composite score combining Quality (22), Value (26), and Momentum (33) factor ranks across MoatMap's 20,000+ stock universe.

Does Generate Biomedicines, Inc. have an economic moat?

Generate Biomedicines, Inc. (GENB) has a Quality factor score of 22/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Generate Biomedicines, Inc. a buy, hold, or sell?

MoatMap's current signal for Generate Biomedicines, Inc. (GENB) is Strong Sell, based on a StockRank of 8/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Generate Biomedicines, Inc. in?

Generate Biomedicines, Inc. (GENB) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

GENB

STRONG SELL

Generate Biomedicines, Inc. · Healthcare · United States · $1.7B · Avg Vol: $12M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

—

D/E

0.1x

Dividend %

—

COMPANY DESCRIPTION

Generate Biomedicines, Inc. is a biotechnology company pioneering a machine learning-powered generative biology platform to create novel protein therapeutics. It leverages AI and computational biology to design and optimize drugs from scratch, accelerating discovery and expanding the druggable target space. This is a cutting-edge biotech firm at the forefront of AI-driven drug discovery, aiming to revolutionize therapeutic development.

FINANCIAL SUMMARY (USD)

Year	2024	2025	TTM	2026E	2027E	Fwd CAGR
Revenue	20.5M	31.9M	30.3M	25.9M	23.7M	-13.9%
EPS	-2.09	-2.18	-2.07	-2.24	-2.06	—
Shares	127.5M	127.5M	128.2M	—	—	—
Debt	77.0M	68.5M	65.6M	—	—	—
Equity	-434.5M	-616.0M	—	—	—	—
Op CF	-117.8M	-200.6M	-227.8M	—	—	—
Inv CF	-57.7M	116.8M	—	—	—	—
Fin CF	91.3M	28.1M	—	—	—	—

Loading 1Y...

PRICE (1Y)+3.6%

SMA 50SMA 200

$13.40

RSI (14)

16.0

SCORE BREAKDOWN

Quality

ROIC

-89.4%6.9

ROE

—N/A

GP/Assets

-62.2%0.7

Op. Margin

-887.5%7.7

FCF/Assets

—N/A

Piotroski

321.7

Int. Cover

-50.0x6.3

D/E Ratio

0.13x59.4

Current Ratio

9.17x84.7

Value

P/E (TTM)

—N/A

EV/EBITDA

-5.4x25.0

P/FCF

—N/A

P/B

3.4x39.5

P/S

57.5x10.0

Div Yield

—N/A

Momentum

52W High %

—N/A

RS 6M

—N/A

SMA 50/200

—N/A

EPS Rev 4W

0.0%62.5

EPS Rev 12W

+2.6%73.1

EPS Improve

+0%21.8

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$1.7B

P/E (Forward)

-6.6x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GENB are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
GENB	Generate Biomedicines, Inc.(you)	$1.7B	8	STRONG SELL
KARD	Kardigan, Inc.	$1.9B	8	STRONG SELL
OCUL	Ocular Therapeutix, Inc.	$1.9B	9	STRONG SELL
RXRX	Recursion Pharmaceuticals, Inc.	$1.6B	5	STRONG SELL
MAZE	Maze Therapeutics, Inc.	$1.5B	10	STRONG SELL
KLRA	Kailera Therapeutics, Inc.	$2.3B	9	STRONG SELL
TRAX	First Tracks Biotherapeutics, Inc.	$1.2B	7	STRONG SELL
AKTS	Aktis Oncology, Inc.	$1.3B	10	STRONG SELL
AVLN	Avalyn Pharma Inc.	$1.2B	9	STRONG SELL
VRDN	Viridian Therapeutics, Inc.	$2.1B	3	STRONG SELL

Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%

Generate Biomedicines, Inc. (GENB) — Stock Score Summary

Generate Biomedicines, Inc. (GENB) has a MoatMap StockRank of 8/100 based on Quality (22/100), Value (26/100), and Momentum (33/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price	$13.40
Market Cap	$1.7B
P/E (Forward)	-6.58
Price/Book	3.38
Return on Invested Capital	-89.4%
Debt/Equity	0.13x
Gross Margin	0.0%
Operating Margin	-887.5%
Revenue Growth	-18.1%

Generate Biomedicines, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Generate Biomedicines, Inc.’s (GENB) StockRank?: MoatMap’s StockRank for Generate Biomedicines, Inc. (GENB) is 8/100, with a Strong Sell signal. It is a composite of Quality (22), Value (26), and Momentum (33) factor ranks across MoatMap’s 20,000+ stock universe.
Does Generate Biomedicines, Inc. have an economic moat?: Generate Biomedicines, Inc. (GENB) has a Quality factor score of 22/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Generate Biomedicines, Inc. a buy, hold, or sell?: MoatMap’s current signal for Generate Biomedicines, Inc. (GENB) is Strong Sell, based on a StockRank of 8/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Generate Biomedicines, Inc. in?: Generate Biomedicines, Inc. (GENB) operates in the Healthcare sector, specifically the Biotechnology industry (United States).